This new compound is orally bioavailable and heading into Phase 2 testing in Japan for hearing loss. They're targeting a novel condition with no current treatments to expedite the approval process by demonstrating effectiveness and safety. The Recovery Mistake | Anthony Castore, Dave Tate's Table Talk Podcast #403